(5R,7S)-8-[3-iodobenzyl]-1-(3-fluorophenyl)-7-methyl-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide | 1193782-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (5R,7S)-8-[3-iodobenzyl]-1-(3-fluorophenyl)-7-methyl-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide
• 英文别名: (5R,7S)-1-(3-fluorophenyl)-8-(3-iodobenzyl)-7-methyl-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide；(5R,7S)-1-(3-fluorophenyl)-8-[(3-iodophenyl)methyl]-7-methyl-2lambda6-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide；(5R,7S)-1-(3-fluorophenyl)-8-[(3-iodophenyl)methyl]-7-methyl-2λ6-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide
• CAS: 1193782-27-2
• 化学式: C₂₀H₂₃FIN₃O₂S
• 分子量: 515.39
• InChiKey: UFOREQIFXQCGQT-MGPUTAFESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (5R,7S)-8-[3-iodobenzyl]-1-(3-fluorophenyl)-7-methyl-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide 、 2-氯苯基硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 以22%的产率得到(5R,7S)-8-[(2'-chlorobiphenyl-3-yl)methyl]-1-(3-fluorophenyl)-7-methyl-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide
  参考文献：
  名称：

  Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors

  摘要：

  beta-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD). Herein, we describe the discovery of a novel class of BACE-1 inhibitors represented by sulfamide 14g, using a medicinal chemistry strategy to optimize central nervous system (CNS) penetration by minimizing hydrogen bond donors (HBDs) and reducing P-glycoprotein (P-gp) mediated efflux. We have also taken advantage of the combination of structure based drug design (SBDD) to guide the optimization of the sulfamide analogues and the in silico tool WaterMap to explain the observed SAR. Compound 14g is a potent inhibitor of BACE-1 with excellent permeability and a moderate P-gp liability. Administration of 14g to mice produced a significant, dose-dependent reduction in central A beta(X-40) levels at a free drug exposure equivalent to the whole cell IC50 (100 nM). Furthermore, studies of the P-gp knockout mouse provided evidence that efflux transporters affected the amount of A beta lowering versus that observed in wild-type (WT) mouse at an equivalent dose.

  DOI：

  10.1021/jm3009426
• 作为产物：
  描述：

  3-氟苯胺 在 氨 、 氢气 、 palladium(II) hydroxide 、 溶剂黄146 、 三乙胺 、 3-(imidazole-1-sulfonyl)-1-methyl-3H-imidazol-1-ium triflate 作用下， 以 甲醇 、 二氯甲烷 、 水 、 1,2-二氯乙烷 、 乙腈 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 30.5h， 生成 (5R,7S)-8-[3-iodobenzyl]-1-(3-fluorophenyl)-7-methyl-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide
  参考文献：
  名称：

  Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors

  摘要：

  beta-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD). Herein, we describe the discovery of a novel class of BACE-1 inhibitors represented by sulfamide 14g, using a medicinal chemistry strategy to optimize central nervous system (CNS) penetration by minimizing hydrogen bond donors (HBDs) and reducing P-glycoprotein (P-gp) mediated efflux. We have also taken advantage of the combination of structure based drug design (SBDD) to guide the optimization of the sulfamide analogues and the in silico tool WaterMap to explain the observed SAR. Compound 14g is a potent inhibitor of BACE-1 with excellent permeability and a moderate P-gp liability. Administration of 14g to mice produced a significant, dose-dependent reduction in central A beta(X-40) levels at a free drug exposure equivalent to the whole cell IC50 (100 nM). Furthermore, studies of the P-gp knockout mouse provided evidence that efflux transporters affected the amount of A beta lowering versus that observed in wild-type (WT) mouse at an equivalent dose.

  DOI：

  10.1021/jm3009426

文献信息

• [EN] NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] NOUVELLE CLASSE DE SPIRO PIPÉRIDINES POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：PFIZER

  公开号：WO2009136350A1

  公开（公告）日：2009-11-12

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其在规范中定义的结构为化学式（I）的药用可接受盐。同时还揭示了相应的药用组合物、治疗方法、合成方法和中间体。
• Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases
  申请人：Brodney Michael A.

  公开号：US20110046160A1

  公开（公告）日：2011-02-24

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物及其药用可接受盐，其中该化合物具有规范中定义的公式（I）的结构。同时还公开了相应的药物组合物、治疗方法、合成方法和中间体。
• NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Pfizer Inc.

  公开号：EP2300484B1

  公开（公告）日：2011-12-14